- Home
- TCBI vs MIRM Comparison
TCBI vs MIRM Comparison
Compare TCBI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBI
- MIRM
- Stock Information
- Founded
- TCBI 1996
- MIRM 2018
- Country
- TCBI United States
- MIRM United States
- Employees
- TCBI N/A
- MIRM N/A
- Industry
- TCBI Major Banks
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- TCBI Finance
- MIRM Health Care
- Exchange
- TCBI Nasdaq
- MIRM Nasdaq
- Market Cap
- TCBI 3.9B
- MIRM 3.3B
- IPO Year
- TCBI N/A
- MIRM 2019
- Fundamental
- Price
- TCBI $86.39
- MIRM $73.48
- Analyst Decision
- TCBI Hold
- MIRM Strong Buy
- Analyst Count
- TCBI 12
- MIRM 11
- Target Price
- TCBI $83.25
- MIRM $76.09
- AVG Volume (30 Days)
- TCBI 383.1K
- MIRM 700.8K
- Earning Date
- TCBI 10-16-2025
- MIRM 11-11-2025
- Dividend Yield
- TCBI N/A
- MIRM N/A
- EPS Growth
- TCBI N/A
- MIRM N/A
- EPS
- TCBI 2.50
- MIRM N/A
- Revenue
- TCBI $936,954,000.00
- MIRM $429,161,000.00
- Revenue This Year
- TCBI $47.34
- MIRM $53.14
- Revenue Next Year
- TCBI $9.49
- MIRM $19.83
- P/E Ratio
- TCBI $34.54
- MIRM N/A
- Revenue Growth
- TCBI N/A
- MIRM 62.33
- 52 Week Low
- TCBI $59.37
- MIRM $36.88
- 52 Week High
- TCBI $94.61
- MIRM $78.10
- Technical
- Relative Strength Index (RSI)
- TCBI 54.43
- MIRM 54.95
- Support Level
- TCBI $82.50
- MIRM $70.49
- Resistance Level
- TCBI $87.67
- MIRM $74.96
- Average True Range (ATR)
- TCBI 2.01
- MIRM 1.95
- MACD
- TCBI -0.10
- MIRM -0.82
- Stochastic Oscillator
- TCBI 66.70
- MIRM 43.98
About TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.